Migraine biotech Vedana Therapeutics raises $46 million Series A to advance preclinical pipeline
read at Endpoints ↗DealPositive
Vedana Therapeutics, a new biotech focused on migraine, has announced its emergence from stealth mode after securing a Series A financing round.
The company raised $46 million from investors, which will be used to develop preclinical candidates aimed at providing a cure-like solution that could eliminate migraine attacks rather than just reducing their frequency.
The funding positions Vedana to advance its pipeline, and the announcement highlights growing investor interest in innovative migraine therapies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Migraine biotech Vedana Therapeutics makes its debut with $46M Series A”
read at Endpoints ↗101 words · retrieved Jun 17
comments(0)
5-min edit window · permanent after that